Exchange: NASDAQ·Updated 07:44 PM EST

IRON News

News
all
press releases
Disc Medicine, Inc. (IRON) Upgraded to Buy: Here's What You Should Know
Disc Medicine, Inc. (IRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Disc Medicine, Inc. (IRON) Upgraded to Buy: Here's What You Should Know
Disc Medicine, Inc. (IRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
More News
The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Disc Medicine, Inc. (IRON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Morgan Stanley increased their price objective on Disc Medicine from $92.00 to $104.00 and gave the company an "overweight" rating in a report on Wednesday...
MarketBeat
Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript...
SeekingAlpha
Pictet Asset Management Holding SA decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 67.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,233 shares of the company's stock after sell...
MarketBeat
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary- Two unrelated...
PR Newswire
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.read more...
Benzinga
Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.read more...
Benzinga
Biotechnology is delivering a fresh wave of developments that could reshape investor expectations for Disc Medicine (NASDAQ:IRON), Silence Therapeutics (NASDAQ:SLN), NeOnc Technologies Holdings (NASDAQ:NTHI), and Alaunos Therapeutics (NASDAQ:TCRT).
24-7 Market News
Futures Rise As Dip Buyers Rush Back Into Chips After Worst Nasdaq Week Since Liberation Day US futures are higher - but well off session highs hit before the European open - as dip buyers storm back into chipmakers after the Nasdaq's worst week since the April 2025 tariff turmoil...
Zero Hedge

Advertisement|Remove ads.